東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Evaluation of quantitative MR imagin...

Xing, Ye.

FindBook

Google Book

Amazon

博客來

Evaluation of quantitative MR imaging biomarkers for assessment of breast cancer risk.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Evaluation of quantitative MR imaging biomarkers for assessment of breast cancer risk./
作者:	Xing, Ye.
面頁冊數:	137 p.
附註:	Source: Dissertation Abstracts International, Volume: 72-05, Section: B, page: 2925.
Contained By:	Dissertation Abstracts International72-05B.
標題:	Engineering, Biomedical. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3447187
ISBN:	9781124517452

Evaluation of quantitative MR imaging biomarkers for assessment of breast cancer risk.
Xing, Ye.

Evaluation of quantitative MR imaging biomarkers for assessment of breast cancer risk. - 137 p.

Source: Dissertation Abstracts International, Volume: 72-05, Section: B, page: 2925.

Thesis (Ph.D.)--University of Pennsylvania, 2010.

The assessment of breast cancer risk is important in determination of personalized breast cancer prevention strategy and evaluation of the effectiveness of intervention drugs. In this thesis, two MR imaging biomarkers, parenchyma volume and parenchyma enhancement were proposed, quantified and tested their abilities to assess the breast cancer risk. This thesis is a sub-study of a pre-existing two-armed, double-blinded clinical trial in which patients were randomized into one treatment group receiving tamoxifen daily for one year and placebo group receiving no treatment and received repeated MRI scans every 6 months for 2 years. The quantification of these biomarkers involves developing a quantitative analyzing pipeline. The test of the association between the biomarker and breast cancer risk changes was performed by comparing the mean response of the biomarker over time between groups. The results showed that the parenchyma enhancement rate in the treatment group decreases significantly compared with placebo group; the parenchyma volume in treatment group decreases more quickly than that in placebo group but was not statistically significant at p-value level of 0.05. The conclusion of this thesis is these MR imaging biomarkers are correlated with breast cancer risk changes and have the potential to be surrogate endpoints for breast cancer preventive trials.

ISBN: 9781124517452Subjects--Topical Terms:

1017684
Engineering, Biomedical.

Evaluation of quantitative MR imaging biomarkers for assessment of breast cancer risk.
LDR:02272nam a2200277 4500 001 1963732
005 20141007080311.5
008 150210s2010 ||||||||||||||||| ||eng d
020 $a 9781124517452
035 $a (MiAaPQ)AAI3447187
035 $a AAI3447187
040 $a MiAaPQ $c MiAaPQ
100 1 $a Xing, Ye. $3 2100042
245 1 0 $a Evaluation of quantitative MR imaging biomarkers for assessment of breast cancer risk.
300 $a 137 p.
500 $a Source: Dissertation Abstracts International, Volume: 72-05, Section: B, page: 2925.
500 $a Adviser: Mitchell Schnall.
502 $a Thesis (Ph.D.)--University of Pennsylvania, 2010.
520 $a The assessment of breast cancer risk is important in determination of personalized breast cancer prevention strategy and evaluation of the effectiveness of intervention drugs. In this thesis, two MR imaging biomarkers, parenchyma volume and parenchyma enhancement were proposed, quantified and tested their abilities to assess the breast cancer risk. This thesis is a sub-study of a pre-existing two-armed, double-blinded clinical trial in which patients were randomized into one treatment group receiving tamoxifen daily for one year and placebo group receiving no treatment and received repeated MRI scans every 6 months for 2 years. The quantification of these biomarkers involves developing a quantitative analyzing pipeline. The test of the association between the biomarker and breast cancer risk changes was performed by comparing the mean response of the biomarker over time between groups. The results showed that the parenchyma enhancement rate in the treatment group decreases significantly compared with placebo group; the parenchyma volume in treatment group decreases more quickly than that in placebo group but was not statistically significant at p-value level of 0.05. The conclusion of this thesis is these MR imaging biomarkers are correlated with breast cancer risk changes and have the potential to be surrogate endpoints for breast cancer preventive trials.
590 $a School code: 0175.
650 4 $a Engineering, Biomedical. $3 1017684
650 4 $a Health Sciences, Radiology. $3 1019076
690 $a 0541
690 $a 0574
710 2 $a University of Pennsylvania. $3 1017401
773 0 $t Dissertation Abstracts International $g 72-05B.
790 $a 0175
791 $a Ph.D.
792 $a 2010
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3447187